Though LXR agonist treatment has been shown to affect metabolism significantly during diet-induced obesity resulting in attenuated weight gain, induction of white adipocyte lipolysis and fatty acid oxidation40, hepatic steatosis41 and improved insulin sensitivity42,43, we reasoned, if loss of TG2 in macrophages affects primarily inflammation, LXR agonist treatment will result in a similar phenotype in mice carrying and in mice lacking TG2 in bone marrow-derived cells exposed to HFD. The gene discussed is TGM2; the disease is obesity due to melanocortin 4 receptor deficiency.